Abstract 157P
Background
REILD is a rare but potentially life-threatening adverse event of Y90-SIRT, with a previously reported incidence of 0-8%. To date, risk factors for REILD remain poorly defined. We aim to define risk factors for REILD in a large cohort of patients treated with Y90-SIRT for HCC from a single institution.
Methods
This is a retrospective study of consecutive patients treated with Y90 for locally advanced HCC from 2007 to 2019 at the National Cancer Centre Singapore and Singapore General Hospital. Excluded were patients lost to follow-up and those with other concomitant cancer. REILD was defined by the presence of ascites and jaundice between 4-8 weeks post-Y90-SIRT in the absence of tumor progression or bile duct obstruction. Patient demographics, clinical history, pertinent laboratory values and radiological findings were collected. Ethical approval was granted by the Institutional Review Board (IRB 2017/2541).
Results
593 patients received Y90 during the study period, of which 472 met the inclusion/exclusion criteria. 12 patients (2.54%) developed REILD. Risk factors for REILD included baseline grade 2 ALBI score (P=0.039), BCLC C HCC (P=0.003), AFP ≥400 pre-Y90 (P=0.005), and radiological ascites (P=0.003). T/N ratio and total administered Y90 dose did not correlate with REILD development. No patients demised from REILD. However, median overall survival (OS) post-Y90 was shorter for REILD patients (22.3 weeks) compared to non-REILD patients (49.1 weeks) (P=0.017). Table: 157P
Baseline characteristics | REILD | Non-REILD | P | |
N = 12 | N = 460 | |||
ALBI grade | 1 | 0 (0.00%) | 130 (28.3%) | 0.039 |
2 | 12 (100%) | 297 (64.6%) | ||
3 | 0 (0.00%) | 33 (7.17%) | ||
BCLC stage | A | 0 (0.00%) | 77 (16.7%) | 0.003 |
B | 0 (0.00%) | 171 (37.2%) | ||
C | 12 (100%) | 208 (45.2%) | ||
D | 0 (0.00%) | 4 (0.87%) | ||
AFP Pre-Y90 | <400 | 2 (20.0%) | 267 (63.9%) | 0.005 |
≥400 | 8 (80.0%) | 151 (36.1%) | ||
NA | 2 | 42 | ||
Radiological ascites | N | 9 (75.0%) | 424 (92.2%) | 0.003 |
Y | 3 (25.0%) | 36 (7.8%) | ||
T/N ratio | Mean (SD) | 3.67 (2.17) | 4.30 (4.14) | 0.369 |
Median (IQR) | 3.46 (2.15-5.37) | 3.12 (2.07-5.31) | ||
Y90 dose (Gbq) | Mean (SD) | 1.73 (1.03) | 1.70 (0.955) | 0.454 |
Median (IQR) | 1.50 (1.33-1.90) | 1.47 (0.980-2.30) |
Conclusions
Risk factors for REILD are varied and multifactorial. HCC stage and underlying liver function are major determinants of REILD risk. The risk of REILD is not dependent on factors related to Y90-SIRT delivery such as median T/N ratio and radiation dose delivered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CIRB.
Funding
Has not received any funding.
Disclosure
P. Chow: Financial Interests, Institutional, Advisory Role: Sirtex Medical; Financial Interests, Institutional, Speaker’s Bureau: Sirtex Medical; Financial Interests, Institutional, Research Funding: Sirtex Medical. All other authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract